Prof Bullinger speaks with ecancer at EHA 23 about the clinical implications for mutations detected in AML patients cells.

He highlights key mutations including p53, IDH and Flt3 mutations, some of which are treatable with targeted agents such as midostaurin, others acting as prognostic markers.

He highlights the impact of kinase inhibitors on survival, and the factors of age and persistent disease in treatment management.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.